๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Bioavailability of pseudoephedrine from controlled release formulations in the presence of guaifenesin in human volunteers

โœ Scribed by Vaishali Pade; Jagadeesh Aluri; Linda Manning; Salomon Stavchansky


Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
498 KB
Volume
16
Category
Article
ISSN
0142-2782

No coin nor oath required. For personal study only.

โœฆ Synopsis


A multiple-dose bioequivalence study with six healthy human volunteers was conducted. The bioavailability of an experimental controlled release tablet containing pseudoephedrine was compared with a marketed controlled release pseudoephedrine capsule in a three-way crossover study. Plasma samples, collected serially after oral drug administration, were analyzed for pseudoephedrine content using a specific HPLC method with UV detection. The bioavailability parameters, area under the concentration-time curve (AUC), maximum plasma concentration C,, , and time to peak ( Tma) were obtained from the plasma concentration-time data. Additionally, model independent pharmacokinetic parameters were estimated. Anaylsis of variance of the data revealed no statistically significant differences between the test and the reference formulation. The presence of guaifenesin in the sustained release tablet did not influence pseudoephedrine bioavailability. The relative bioavailability of the tablet dosage form with respect to the capsule was found to be 100.8 %. Classical and Westlake 95 % confidence limits as well as the two one-sided r test, proposed by Schuirmann, and the Anderson-Hauck power analysis supported the inference that the two formulations demonstrated comparable bioavailability, even in the presence of guaifenesin.

Using a non-linear regression program, it was found that the parmacokinetics of pseudoephedrine followed a simple one-compartment disposition model with no lag time. Additionally, an in vitro-in vivo correlation, based on the estimation of cumulative relative fraction absorbed, was developed between the absorption of pseudoephedrine in humans and the in vitro dissolution time.


๐Ÿ“œ SIMILAR VOLUMES


Bioavailability of dextromethorphan (as
โœ S. Demirbas; L. Reyderman; S. Stavchansky ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 144 KB ๐Ÿ‘ 2 views

A multiple dose bioavailability study with six healthy male human volunteers was conducted. The bioavailability of an experimental sustained release tablet containing dextromethorphan hydrobromide (DXP-HBr), was compared with a marketed sustained release DXP-HBr suspension in a three-way crossover s

THE RELATIVE BIOAVAILABILITY OF TWO MARK
โœ C. L. Lippert; T. Arumugham; V. O. Bhargava; M. Eller; S. J. Weir ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 472 KB ๐Ÿ‘ 2 views

This study was conducted to determine the relative bioavailability of Dilacorm XR capsules compared to CardizemD CD capsules at both low (180mgdPL) and high (540mgd-') dose levels. Trough and serial plasma samples were obtained and pharmacokinetic parameters were calculated from the steady state con